Quarterly Results
ELMD Earnings Forecast
Looking ahead, ELMD remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2026/Q2 project quarter revenue of 18.05M and an EPS of 0.26.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2026 have been Revise Upward by 0.07%, while EPS estimates have been Revise Upward by 5.04%. For the upcoming Q2 2026, revenue estimates have been adjusted Revise Upward by 0.42% . These revisions correlate with a 19.50% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in ELMD long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how ELMD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ELMD sees a -1.80% change in stock price 10 days leading up to the earnings, and a -0.05% change 10 days following the report. On the earnings day itself, the stock moves by +0.88%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 3.82% on the day following the earnings release and then changed by 4.49% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of ELMD's latest earnings report for FY2026Q1?
ELMD reported its FY2026Q1 earnings on 2025-11-12, showcasing a revenue of 16.89M against an estimate of 16.63M, resulting in a 1.52% surprise. The EPS was 0.25, surpassing the expected 0.22 by 13.64% . The stock experienced a 3.82% price change on the earnings day and a -3.39% change over the next five days, reflecting market reactions to the results.
How did ELMD's stock price react after the FY2026Q1 earnings release?
Following ELMD's FY2026Q1 earnings announcement on 2025-11-12, the stock price moved by 3.82% on the day of the release. Over the subsequent five days, it saw a -3.39% change. Historically, ELMD's stock price tends to shift by an average of -1.80% in the 10 days leading up to earnings and -0.05% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for ELMD for 2026/Q2?
For 2026/Q2, analysts estimate ELMD’s annual revenue to reach 18.05M, while the EPS is projected at 0.26. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.07% and EPS estimates Revise Upward by 0.42% over the past three months, indicating analyst expectation in the company’s performance.
How does ELMD's stock price correlate with earnings forecast revisions?
The correlation between ELMD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Upward by 0.07%, while EPS estimates moved Revise Upward by 0.42% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from ELMD's next earnings report?
Based on historical trends, ELMD's stock price typically moves by -1.80% in the 10 days before its earnings and -0.05% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.26 and revenue of 18.05M.
What is the sentiment in Electromed Inc (ELMD) Q1 2026 Earnings Call Summary?
The earnings call highlights strong financial performance with a 15% revenue increase and 38% rise in operating income. The strategic expansion of sales territories and focus on the bronchiectasis market are promising. The $10 million stock repurchase program indicates confidence in the company's value. However, economic uncertainties and unclear management responses about hospital sales create slight concerns. Overall, the sentiment is positive due to strong growth metrics, strategic initiatives, and shareholder returns.
